Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Unknown 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Renal Cell 145Kidney Neoplasms 42Prostatic Neoplasms 16Neoplasm Metastasis 16Urinary Bladder Neoplasms 13Neoplasms 9Clear-cell metastatic renal cell carcinoma 6Breast Neoplasms 5Kidney Diseases 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Urologic Neoplasms 3Urogenital Neoplasms 3Urethral Neoplasms 3Thyroid Neoplasms 3Ovarian Neoplasms 3Multiple Myeloma 3Gastrointestinal Stromal Tumors 3Carcinoma 3Stomach Neoplasms 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Myeloproliferative Disorders 2Melanoma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2

Interventions

Gemcitabine 24Cisplatin 18Carboplatin 10Paclitaxel 9Specimen Handling 6Nivolumab 6Doxorubicin 6Docetaxel 6pembrolizumab 5Magnetic Resonance Spectroscopy 5cabozantinib 4avelumab 4Vinblastine 4Radiotherapy 4Methotrexate 4Fluorouracil 4enfortumab vedotin 3atezolizumab 3aflibercept 3Trastuzumab 3Sunitinib 3Ramucirumab 3Platinum 3Ipilimumab 3CTLA-4 Antigen 3Biopsy 31,2-diaminocyclohexaneplatinum II citrate 3vinflunine 2pegfilgrastim 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urethral Neoplasms × Sunitinib × Genitourinary × Clear all
NCT01089088 2018-10-26

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Cardiff University

Phase 2 Completed
63 enrolled
Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00397488 2016-01-25

Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
78 enrolled 6 charts
Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT01118039 2013-08-07

Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
41 enrolled
Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡